Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Verkerk

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Cell|March 29, 2024
Generating and using real-world data: A worthwhile uphill battleK Verkerk, E E Voest
ESMO Open|March 20, 2025
Authors response to Letter re: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP) molecular complexity and response to targeted therapyK Verkerk, E E Voest
European Journal of Pain (London, England)|January 8, 2015
Prognosis and course of pain in patients with chronic non-specific low back pain: A 1-year follow-up cohort studyK Verkerk, P A J Luijsterburg, M W Heymans, et al.
Nature|April 15, 2026
Prospective evaluation of genomics-guided off-label treatmentK Verkerk, A C Spiekman, S F Haj Mohammad, et al.
ESMO Open|January 8, 2025
The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)K Verkerk, L J Zeverijn, J van de Haar, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Cell|March 29, 2024
Generating and using real-world data: A worthwhile uphill battleK Verkerk, E E Voest
ESMO Open|March 20, 2025
Authors response to Letter re: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP) molecular complexity and response to targeted therapyK Verkerk, E E Voest
European Journal of Pain (London, England)|January 8, 2015
Prognosis and course of pain in patients with chronic non-specific low back pain: A 1-year follow-up cohort studyK Verkerk, P A J Luijsterburg, M W Heymans, et al.
Nature|April 15, 2026
Prospective evaluation of genomics-guided off-label treatmentK Verkerk, A C Spiekman, S F Haj Mohammad, et al.
ESMO Open|January 8, 2025
The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)K Verkerk, L J Zeverijn, J van de Haar, et al.
Pageof 1